secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-01-16T23:59:59+00:00
Accession:  0001437749-25-001245
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros narsoplimab sensitivity analyses confirm survival benefit; BLA resubmission planned this quarter
--------------------------------------------------------------------------------

- Sensitivity analyses show HR 0.24–0.42 vs external control, p-values 0.0124 to <0.00001, confirming primary endpoint robustness.
- Primary endpoint (Dec 19): HR=0.32 (95% CI 0.23–0.44), p<0.00001, over 3-fold mortality reduction in TA-TMA patients.
- Omeros targets BLA resubmission to FDA later this quarter and European MAA submission by mid-year.
- Narsoplimab has been well tolerated across trials with no safety signal of concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925001245/0001437749-25-001245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925001245/omer20250116c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-001245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer